首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   27751篇
  免费   2700篇
  国内免费   1026篇
耳鼻咽喉   273篇
儿科学   437篇
妇产科学   303篇
基础医学   3171篇
口腔科学   418篇
临床医学   2848篇
内科学   4824篇
皮肤病学   568篇
神经病学   1436篇
特种医学   1140篇
外国民族医学   2篇
外科学   4087篇
综合类   3162篇
现状与发展   3篇
一般理论   4篇
预防医学   2426篇
眼科学   752篇
药学   2688篇
  16篇
中国医学   873篇
肿瘤学   2046篇
  2024年   18篇
  2023年   253篇
  2022年   328篇
  2021年   1083篇
  2020年   870篇
  2019年   881篇
  2018年   998篇
  2017年   811篇
  2016年   856篇
  2015年   1048篇
  2014年   1352篇
  2013年   1393篇
  2012年   2075篇
  2011年   2062篇
  2010年   1418篇
  2009年   1259篇
  2008年   1678篇
  2007年   1717篇
  2006年   1554篇
  2005年   1330篇
  2004年   1406篇
  2003年   1439篇
  2002年   1279篇
  2001年   1029篇
  2000年   808篇
  1999年   528篇
  1998年   200篇
  1997年   194篇
  1996年   136篇
  1995年   116篇
  1994年   106篇
  1993年   93篇
  1992年   176篇
  1991年   127篇
  1990年   137篇
  1989年   120篇
  1988年   107篇
  1987年   87篇
  1986年   78篇
  1985年   58篇
  1984年   52篇
  1983年   37篇
  1982年   29篇
  1981年   17篇
  1980年   20篇
  1979年   24篇
  1977年   10篇
  1976年   12篇
  1975年   9篇
  1974年   12篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs.  相似文献   
3.
4.
Background and aimsDeterioration of anthropometric and lung function parameters was shown to precede the onset of cystic fibrosis-related diabetes (CFRD) in adults. In children, studies have been conducted in small cohorts with relatively short observation period. Study objectives were to document the longitudinal trends of anthropometric, pulmonary, nutritional and metabolic parameters from cystic fibrosis (CF) diagnosis to the ascertainment of abnormal glucose tolerance and identify parameters associated with the incidence of such abnormalities in a pediatric CF cohort.Methods and resultsRetrospective cohort study of 281 children with CF. Longitudinal trends of anthropometric, lung function, nutritional and metabolic data were generated from CF diagnosis to the ascertainment of abnormal glucose tolerance defined as the presence of either impaired glucose tolerance (IGT), unconfirmed CFRD or CFRD. Cox models and Kaplan–Meier curves were used to identify factors associated with developing abnormal glucose tolerance.Forty-five percent of cohort had normal glucose tolerance (NGT), 27% IGT, 10% unconfirmed CFRD and 18% CFRD. Children who developed CFRD displayed lower height z-scores from a very early age. Conversely, HbA1c levels began to rise closer to CFRD ascertainment. Height z-scores (HR: 0.45; CI 95% [0.29–0.69]) and HbA1c (HR: 2.43; CI 95% [1.86–3.18]) in years preceding ascertainment were associated with the risk of developing CFRD.ConclusionChildren who developed CFRD display distinctive trends for height z-scores from a very early age, whereas HbA1c appears as a marker of established glucose metabolism derangements.  相似文献   
5.
Integrase strand transfer inhibitors (InSTIs) have been widely used in recent years because of their high genetic barrier to resistance. The World Health Organization (WHO) has recommended dolutegravir (DTG)-containing regimens as the preferred first- and second-line antiretroviral therapy (ART) regimens for people living with human immunodeficiency virus (HIV)[1]. During the long-term treatment process, the appearance of drug resistance mutations to InSTIs is inevitable. A meta-analysis has shown that the resistance rate among InSTI treatment-experienced patients is 3.9% (Raltegravir, RAL), 1.2% (Elvitegravir, EVG), and 0.1% (DTG)[2]. However, resistance to InSTIs has not been reported in treatment-naive populations.  相似文献   
6.
ObjectiveTo evaluate differences in postoperative pain control and opioids requirement in thoracic surgical patients following implementation of an Enhanced Recovery after Thoracic Surgery protocol with a comprehensive postoperative pain management strategy.Material and MethodsA retrospective analysis of a prospectively maintained database of patients undergoing pulmonary resections by robotic thoracoscopy or thoracotomy from January 1, 2017, to January 31, 2019, was conducted. Multimodal pain management strategy (opioid-sparing analgesics, infiltration of liposomal bupivacaine to intercostal spaces and surgical sites, and elimination of thoracic epidural analgesia use in thoracotomy patients) was implemented as part of Enhanced Recovery after Thoracic Surgery on February 1, 2018. Outcome metrics including patient-reported pain levels, in-hospital and postdischarge opioids use, postoperative complications, and length of stay were compared before and after protocol implementation.ResultsIn total, 310 robotic thoracoscopy and 62 thoracotomy patients met the inclusion criteria. This pain management strategy was associated with significant reduction of postoperative pain in both groups with an overall reduction of postoperative opioids requirement. Median in-hospital opioids use (morphine milligram equivalent per day) was reduced from 30 to 18.36 (P = .009) for the robotic thoracoscopy group and slightly increased from 15.48 to 21.0 (P = .27) in the thoracotomy group. More importantly, median postdischarge opioids prescribed (total morphine milligram equivalent) was significantly reduced from 480.0 to 150.0 (P < .001) and 887.5 to 150.0 (P < .001) for the thoracoscopy and thoracotomy groups, respectively. Similar short-term perioperative outcomes were observed in both groups before and following protocol implementation.ConclusionsImplementation of Enhanced Recovery after Thoracic Surgery allows safe elimination of epidural use, better pain control, and less postoperative opioids use, especially a drastic reduction of postdischarge opioid need, without adversely affecting outcomes.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号